Immunopathology of and Potential Therapeutics for Secondary Hemophagocytic Lymphohistiocytosis/macrophage Activation Syndrome: a Translational Perspective

Overview

Journal Exp Mol Med

Specialties Biochemistry
Molecular Biology

Date 2024 Mar 6

PMID 38448692

Authors

Tram T T Nguyen

Yoon Tae Kim

Geunyeol Jeong

Mirim Jin

Affiliations

Soon will be listed here.

Abstract

Secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome (sHLH/MAS) is a life-threatening immune disorder triggered by rheumatic disease, infections, malignancies, or medications. Characterized by the presence of hemophagocytic macrophages and a fulminant cytokine storm, sHLH/MAS leads to hyperferritinemia and multiorgan failure and rapidly progresses to death. The high mortality rate and the lack of specific treatments necessitate the development of a new drug. However, the complex and largely unknown immunopathologic mechanisms of sHLH/MAS, which involve dysfunction of various immune cells, diverse etiologies, and different clinical contexts make this effort challenging. This review introduces the terminology, diagnosis, and clinical features of sHLH/MAS. From a translational perspective, this review focuses on the immunopathological mechanisms linked to various etiologies, emphasizing potential drug targets, including key molecules and signaling pathways. We also discuss immunomodulatory biologics, existing drugs under clinical evaluation, and novel therapies in clinical trials. This systematic review aims to provide insights and highlight opportunities for the development of novel sHLH/MAS therapeutics.

Citing Articles

Alternative mRNA polyadenylation regulates macrophage hyperactivation via the autophagy pathway.

Chen Y, Chen B, Li J, Li H, Wang G, Cai X Cell Mol Immunol. 2024; 21(12):1522-1534.

PMID: 39537902 PMC: 11607066. DOI: 10.1038/s41423-024-01237-8.

Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms.

Wu Y, Sun X, Kang K, Yang Y, Li H, Zhao A J Hematol Oncol. 2024; 17(1):106.

PMID: 39511607 PMC: 11542428. DOI: 10.1186/s13045-024-01621-x.

Hemophagocytosis of the Hilar Pulmonary Lymph Nodes Is a More Sensitive Indicator of the Severity of COVID-19 Disease than Bone Marrow Hemophagocytosis.

Jusovic-Stocanin A, Kaemmerer E, Ihle H, Autsch A, Kleemann S, Sanft J Diseases. 2024; 12(10).

PMID: 39452484 PMC: 11506861. DOI: 10.3390/diseases12100241.

Into the storm: the imbalance in the yin-yang immune response as the commonality of cytokine storm syndromes.

Armstrong A, Tang Y, Mukherjee N, Zhang N, Huang G Front Immunol. 2024; 15:1448201.

PMID: 39318634 PMC: 11420043. DOI: 10.3389/fimmu.2024.1448201.

Machine Learning of Laboratory Data in Predicting 30-Day Mortality for Adult Hemophagocytic Lymphohistiocytosis.

Zhou J, Xie M, Dong N, Xie M, Liu J, Wang M J Clin Immunol. 2024; 45(1):12.

PMID: 39302504 DOI: 10.1007/s10875-024-01806-6.

References

Khan H, Ansar I, Kontos N, Kumar S, Lyons H . Report of a Fatal Case of Hemophagocytic Lymphohistiocytosis Syndrome and a Review of the Literature. Cureus. 2021; 12(12):e12049. PMC: 7797430. DOI: 10.7759/cureus.12049. View

Gothe F, Spegarova J, Hatton C, Griffin H, Sargent T, Cowley S . Aberrant inflammatory responses to type I interferon in STAT2 or IRF9 deficiency. J Allergy Clin Immunol. 2022; 150(4):955-964.e16. DOI: 10.1016/j.jaci.2022.01.026. View

Lee J, Shin E . The type I interferon response in COVID-19: implications for treatment. Nat Rev Immunol. 2020; 20(10):585-586. PMC: 8824445. DOI: 10.1038/s41577-020-00429-3. View

Parodi A, Davi S, Pringe A, Pistorio A, Ruperto N, Magni-Manzoni S . Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum. 2009; 60(11):3388-99. DOI: 10.1002/art.24883. View

Olin R, Nichols K, Naghashpour M, Wasik M, Shelly B, Stadtmauer E . Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis. Am J Hematol. 2008; 83(9):747-9. PMC: 2757271. DOI: 10.1002/ajh.21236. View

Papatriantafyllou M . Cytokines: GM-CSF in focus. Nat Rev Immunol. 2011; 11(6):370-1. DOI: 10.1038/nri2996. View

Kelly A, Ramanan A . A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol. 2008; 4(11):615-20. DOI: 10.1038/ncprheum0919. View

De Matteis A, Colucci M, Rossi M, Caiello I, Merli P, Tumino N . Expansion of CD4dimCD8+ T cells characterizes macrophage activation syndrome and other secondary HLH. Blood. 2022; 140(3):262-273. DOI: 10.1182/blood.2021013549. View

Borgia R, Gerstein M, Levy D, Silverman E, Hiraki L . Features, Treatment, and Outcomes of Macrophage Activation Syndrome in Childhood-Onset Systemic Lupus Erythematosus. Arthritis Rheumatol. 2018; 70(4):616-624. DOI: 10.1002/art.40417. View

10.

Kishida D, Sakaguchi N, Ueno K, Ushiyama S, Ichikawa T, Yoshinaga T . Macrophage activation syndrome in adult dermatomyositis: a case-based review. Rheumatol Int. 2020; 40(7):1151-1162. DOI: 10.1007/s00296-020-04590-9. View

11.

Fox A, Le N, Horby P, van Doorn H, Nguyen V, Nguyen H . Severe pandemic H1N1 2009 infection is associated with transient NK and T deficiency and aberrant CD8 responses. PLoS One. 2012; 7(2):e31535. PMC: 3282732. DOI: 10.1371/journal.pone.0031535. View

12.

Zamai L, Ahmad M, M Bennett I, Azzoni L, Alnemri E, Perussia B . Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med. 1998; 188(12):2375-80. PMC: 2212426. DOI: 10.1084/jem.188.12.2375. View

13.

Hung I, Lung K, Tso E, Liu R, Chung T, Chu M . Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020; 395(10238):1695-1704. PMC: 7211500. DOI: 10.1016/S0140-6736(20)31042-4. View

14.

Sjoelund V, Smelkinson M, Nita-Lazar A . Phosphoproteome profiling of the macrophage response to different toll-like receptor ligands identifies differences in global phosphorylation dynamics. J Proteome Res. 2014; 13(11):5185-97. PMC: 4227906. DOI: 10.1021/pr5002466. View

15.

Carter S, Tattersall R, Ramanan A . Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. Rheumatology (Oxford). 2018; 58(1):5-17. DOI: 10.1093/rheumatology/key006. View

16.

Yin G, Man C, Huang J, Liao S, Gao X, Tian T . The prognostic role of plasma fibrinogen in adult secondary hemophagocytic lymphohistiocytosis. Orphanet J Rare Dis. 2020; 15(1):332. PMC: 7690012. DOI: 10.1186/s13023-020-01622-2. View

17.

Arend W, Palmer G, Gabay C . IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev. 2008; 223:20-38. DOI: 10.1111/j.1600-065X.2008.00624.x. View

18.

Billiau A, Roskams T, van Damme-Lombaerts R, Matthys P, Wouters C . Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. Blood. 2004; 105(4):1648-51. DOI: 10.1182/blood-2004-08-2997. View

19.

Grunfeld C, Gulli R, MOSER A, Gavin L, Feingold K . Effect of tumor necrosis factor administration in vivo on lipoprotein lipase activity in various tissues of the rat. J Lipid Res. 1989; 30(4):579-85. View

20.

Lanier L . The origin and functions of natural killer cells. Clin Immunol. 2000; 95(1 Pt 2):S14-8. DOI: 10.1006/clim.1999.4816. View